Ornithine uptake and the modulation of drug sensitivity in Trypanosoma brucei. Issue 10 (5th July 2017)

• Record Type: Journal Article
• Authors: Macedo, Juan P.; Currier, Rachel B.; Wirdnam, Corina; Horn, David; Alsford, Sam; Rentsch, Doris
• Is Part Of: FASEB journal. Volume 31:Issue 10(2017)
• Page Start: 4649
• Page End: 4660
• Publication Date: 2017-07-05
• Subjects: African trypanosomiasis -- chemotherapy -- eflornithine -- suramin -- histidine; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201700311R
• Languages: English
• ISSNs: 0892-6638

Abstract

ABSTRACT: Trypanosoma brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and metabolism by ornithine decarboxylase (ODC) for survival. Indeed, ODC is the target of the WHO "essential medicine" eflornithine, which is antagonistic to another anti‐HAT drug, suramin. Thus, ornithine uptake has important consequences in T. brucei, but the transporters have not been identified. We describe these amino acid transporters (AATs). In a heterologous expression system, TbAAT10‐1 is selective for ornithine, whereas TbAAT2‐4 transports both ornithine and histidine. These AATs are also necessary to maintain intracellular ornithine and polyamine levels in T. brucei, thereby decreasing sensitivity to eflornithine and increasing sensitivity to suramin. Consistent with competition for histidine, high extracellular concentrations of this amino acid phenocopied a TbAAT2‐4 genetic defect. Our findings established TbAAT10‐1 and TbAAT2‐4 as the parasite ornithine transporters, one of which can be modulated by histidine, but both of which affect sensitivity to important anti‐HAT drugs.—Macedo, J. P., Currier, R. B., Wirdnam, C., Horn, D., Alsford, S., Rentsch, D. Ornithine uptake and the modulation of drug sensitivity in Trypanosoma brucei. FASEB J. 31, 4649–4660 (2017). www.fasebj.org